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Does it make sense to publish cancer survival statistics for every hospital, every year, as has 
been proposed?1 We think not.  
Population-based cancer survival figures, derived from cancer registry data on all cancer 
patients living in a defined region, have been used to highlight geographic, socio-economic 
and international inequalities in survival for many years. Such survival figures have 
underpinned every national cancer strategy in the UK since 1995,2,3 and trends in survival 
have been used to evaluate the impact of those strategies.4 
Unlike hospital-specific survival figures, population-based figures include all cancer patients. 
They are unbiased, and they take precise account of the risk of death from causes other than 
cancer, allowing survival from the cancer to be compared between populations. They are 
thus ideal for evaluating trends in survival, and for regional5 and international comparisons.6 
Persistent inequalities in survival have led politicians to demand survival estimates for ever-
smaller geographies, such as the 209 Clinical Commissioning Groups in England (CCGs, 
population 65,000-880,000). However, producing survival estimates for every CCG that are 
sufficiently robust to be interpreted for managerial purposes, year on year, is extremely 
difficult, even for the most common cancers.7 It can be done for 1-year but not 5-year survival, 
and it requires modelling the entire national dataset of several million cancer patients 
diagnosed over more than 10 years. 
Failure to distinguish between hospital-specific and population-based survival figures has led 
the Department of Health and NHS England to demand routine production of hospital survival 
figures, to judge the performance of every health service “provider” (a single hospital, or a 
group of hospitals that provide cancer services). It has even been suggested that hospital-
specific cancer survival statistics should be produced every year, for each type of cancer, 
and for each stage at diagnosis, as a way of informing “patient choice”.1 A proposal to that 
effect was removed from the 2015 cancer strategy3 only at a very late stage. 
 
We argue that provider-level survival statistics cannot be usefully interpreted for surveillance 
of hospital performance. They are prone to referral bias and to random fluctuation due to 
small numbers; they may lead to spurious comparisons and inappropriate management 
decisions, and they do not support patient choice. The fact that over a million people have 
opted out from the use of their health data other than for their own clinical management 
(http://digital.nhs.uk/catalogue/PUB20527) will introduce bias and further undermine the 
utility of such statistics. We outline some alternatives. 
 
Annual snapshots of outcome data cannot be safely interpreted in isolation. The Association 
of Coloproctology of Great Britain and Ireland publishes such performance data for individual 
colorectal surgeons, such as the 90-day mortality of each surgeon’s patients after planned 
surgery, but the caveats for patients should give pause for thought:  
 “the results this year will not tell us the real situation and will not be completely accurate 
for some surgeons”; 
 “very few [surgeons] do a sufficient number [of procedures], even over the four-year period, 
for these data to allow reliable comparison between surgeons”; 
 “some data may be accurate but other data are not correct and require further verification”; 
and finally  
 “[it is] hard to identify one surgeon as being in charge in one operation” [because surgeons 
work in teams] 
Quite so. 
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Readmission rates, and 30-day or 90-day mortality rates, are short-term outcome measures 
that may relate to a single surgeon or hospital, but fair comparisons require adjustment for 
case-mix, and sufficient numbers to produce statistically robust results.8 One consequence 
could be misplaced confidence where evidence of poor performance is not strong, which can 
be interpreted as reflecting adequate performance. By contrast, population-based outcome 
measures, such as 1-, 5- or 10-year survival, reflect the overall effectiveness of the health 
service in managing all cancer patients in the longer term. Variation in such metrics cannot 
generally be ascribed to a single surgeon or hospital, or a single component of the quality of 
care. 
It is not straightforward to assign a cancer patient to a particular hospital for survival analyses. 
Should it be the hospital where surgery is done, or where radiotherapy is carried out, or the 
specialised hospital to which those patients with complex problems may be transferred? 
Specialised hospitals may appear to confer higher survival if they see few patients for 
palliative care. Conversely, they may appear to confer lower survival if they treat many 
patients with late-stage disease, or complications, despite offering the best treatment. This 
selection process (“referral bias”) can lead to misleading comparisons of survival between 
hospitals. 
At the heart of the problem is the amount of data available for analysis. Most hospitals will 
see too few patients for robust survival estimation. Even for the most common cancers (breast 
and prostate), the average number of new patients seen every year in each hospital is below 
300, and below 50 for the less common cancers. In many hospitals, those numbers will be 
even lower. The numbers are smaller still for each age group and sex (Table 1). Age-
standardisation would be impossible. Producing survival statistics for each cancer, every 
year, for each hospital, further sub-divided by stage at diagnosis, would be even less useful: 
many sub-groups would not contain even one patient. Hospitals cannot be reliably rated, or 
compared with other hospitals, using statistics based on such small numbers of patients. 
 
Ranked bar charts, a common form of comparison, can lead to incorrect judgments about 
year-on-year performance, because they do not take account of the precision of each survival 
estimate.9 Even among 34 Cancer Networks, which covered populations of around 2 million, 
breast cancer survival rankings could change markedly from year to year, due to the small 
numbers of deaths (Figure 1).5 Even in these larger populations, at least three years of data 
are required to obtain more robust survival estimates.  
 
Funnel plots provide a good alternative. Data points outside the control limits (the funnel) 
indicate variation beyond what would be expected by chance, while taking due account of 
precision.9 Funnel plots may still be used to compare some outcome measures for hospitals, 
but the data then need to be adjusted for other factors; and to recognise persistent outliers 
for which performance really needs investigating, we must examine time series, not just a 
single year in which the estimate for a hospital happens to fall outside an arbitrary threshold. 
Providers with consistently poor performance (e.g. the black triangle in Figure 2) can then be 
followed up with in-depth investigation. 
 
We may obtain more insight into the variability of cancer survival from mixed effects models.10 
If we analyse patient data that include hospital characteristics (e.g. the presence of a multi-
disciplinary team, or small caseload), we can ascertain whether a certain characteristic is 
associated with lower survival. The results can identify categories of hospitals for which a 
problem appears to exist, and for which a wider policy change may therefore be required. 
Such analyses avoid inappropriately stigmatising individual hospitals. They also avoid the 
issue of small numbers by grouping hospitals with similar features. They emphasise the 
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importance of factors that may be associated with poor survival, such as poor completeness 
of data on stage at diagnosis, or limited access to radiotherapy, thus pointing the way to 
policies designed to improve outcomes. Instead of “naming and shaming” a local hospital 
based on a single year's data, which can cause lasting and inappropriate damage to public 
confidence, this approach may help identify and correct deficits across the health service as 
a whole. 
 
The attraction of cancer survival statistics for every hospital may be strong, but responsible 
policy-makers will resist it.  
 
Cancer patient survival metrics are of great importance to most patients, and we may 
intuitively feel that comparing cancer survival between hospitals will allow us to identify 
hospitals that are in trouble, and to hold up the “best-performing” providers as exemplars of 
good practice. Population-based survival estimates are relevant for policy-makers, because 
they provide an overview of the effectiveness of the health-care system, so it may seem 
appealing to compare hospital-specific survival estimates – but they are not the same.  
 
League tables may be considered politically desirable to inform “patient choice”,1 but it is not 
helpful to publish league tables in which providers or areas are ranked every year, and for 
the spotlight to fall on those where performance appears to be outside expectation. 
Information that is inaccurate, misleading or uninterpretable is of no use to patients or 
healthcare planners. 
 
The goal is to support long-term improvement in cancer survival. Outcome measures are 
indicators of performance, not proof of failure. Serious attempts to improve hospital 
performance should be based on deeper insight than a tabloid headline.
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Appendix 
Table 1: Number of new cancer patients in England in 2014‡, and average annual number of new patients 
likely to be seen in each of 154 acute hospitals* with one of four common cancers, by age and sex 
   Age in years 
Cancer 
 New 
patients 
<15 15-39 40-49 50-59 60-69 70-79 80+ 
Breast (F) England 46,085 0 1,874 6,733 9,857 11,519 8,580 7,522 
per hospital 299 0 12 44 64 75 56 49 
Prostate England 39,741 1 7 467 4,183 13,448 14,309 7,326 
per hospital 258 0 0 3 27 87 93 48 
Non-Hodgkin 
lymphoma (M) 
 
England 6,448 66 332 435 911 1,611 1,811 1,282 
per hospital 42 0 2 3 6 10 12 8 
Non-Hodgkin 
lymphoma (F) 
England 5,172 20 222 330 663 1,240 1,447 1,250 
per hospital 34 0 1 2 4 8 9 8 
Pancreas (M) England 4,071 1 37 157 460 1,066 1,289 1,061 
per hospital 26 0 0 1 3 7 8 7 
Pancreas (F) England 4,009 1 40 99 365 842 1,226 1,436 
per hospital 26 0 0 1 2 5 8 9 
Sources:  
*http://www.nhsconfed.org/resources/key-statistics-on-the-nhs for number of acute hospitals in 2014 
‡http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/can
cerregistrationstatisticscancerregistrationstatisticsengland for cancer incidence 
Cancer (ICD-10 code): breast (C50); prostate (C61); non-Hodgkin lymphoma (C82-C85); pancreas (C25) 
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Figure 1: One-year relative survival for breast cancer in 34 Cancer Networks in 1996 and 1998. The Cancer 
Network in a darker colour moved from the lowest ranking to almost the highest ranking within 
two years.  
Breast cancer, 1996 Breast cancer, 1998 
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Figure 2: Funnel plots showing an illustration of one-year net survival for all cancers combined in 50 small 
geographical areas, for years 1998, 2003, 2008 and 2013  
